Figure 3 | Scientific Reports

Figure 3

From: Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B

Figure 3

Forest plot displaying the secondary outcomes of serological responses for CHB patients at different time points after treatments with TDF alone and FTC/TDF combination, respectively.

Forest plots showed the comparison of (a) HBeAg loss and (b) HBeAg seroconversion in CHB patients after 48, 96 and 192 weeks of treatments with TDF alone and FTC/TDF combination, respectively.

Back to article page